Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company based in Tarrytown, New York, that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

NASDAQ REGN

$372.71 2.85 (0.76)%

High 378.50 Low 371.32 Volume 723,571 Market Cap 38.60B
12/02/16 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Nov 21

    Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year

    Read on
  • Nov 17

    Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis

    Read on

EVENTS

  • 2016 ACR Annual Meeting
    Nov 16, 2016

  • 25th Annual Credit Suisse Healthcare Conference
    Nov 8, 2016 | 10:00 AM

Events & Presentations

NASDAQ REGN

$372.71 2.85 (0.76)%

High 378.50 Low 371.32 Volume 723,571 Market Cap 38.60B
12/02/16 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information